Apoptosis, P53 and Bcl-2 expression in response to topical calcipotriol therapy for psoriasis

International Journal of Dermatology

Volumn 46, Issue 5, 2007, Pages 468-474

  El Domyati, Moetaz ^a,b   Barakat, Manal ^a   Abdel Razek, Rasha ^a   El Din Anbar, Tag ^a  

^a MINIA UNIVERSITY HOSPITAL   (Egypt)

^b Department of Dermatology ^*  (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIPOTRIOL; PEROXIDASE; PROTEIN BCL 2; PROTEIN P53;

ADULT; APOPTOSIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DATA ANALYSIS; DRUG MECHANISM; DRUG RESPONSE; FEMALE; HEALING; HUMAN; KERATINOCYTE; LYMPHOCYTE; MALE; NICK END LABELING; OINTMENT; PROTEIN EXPRESSION; PSORIASIS VULGARIS; SKIN BIOPSY;

ADULT; AGED; APOPTOSIS; BIOPSY; CALCITRIOL; DERMATOLOGIC AGENTS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; MALE; MIDDLE AGED; PROTO-ONCOGENE PROTEINS C-BCL-2; PSORIASIS; SKIN; TUMOR SUPPRESSOR PROTEIN P53;

EID: 34248159509     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2007.03099.x     Document Type: Article

References (30)

1. Mehlis SL, Gordon KB. The immunology of psoriasis and biologic immunotherapy. J Am Acad Dermatol 2003; 49: 44-50.
2. Laporte M, Galand P, Fokan D, et al. Apoptosis in established and healing psoriasis. Dermatology 2000; 200: 314-316.
3. Raskin CA. Apoptosis and cutaneous biology. J Am Acad Dermatol 1997; 36: 885-896.
4. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science 1995; 267: 1456-1462.
5. Takahashi H, Manabe A, Ishida-Yamamato A, et al. Aberrant expression of apoptosis-related molecules in psoriatic epidermis. J Dermatol Sci 2002; 28: 187-197.
6. Yildiz L, Baris S, Senturk N, et al. Over-expression of Bcl-2 in lymphocytes of psoriatic skin. JEADV 2003; 17: 538-540.
7. Hockenbery D, Nunez G, Milliman C, et al. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990; 348: 334-336.
8. Levine AJ, Momand J, Finlay CA. The P53 tumour suppressor gene. Nature 1991; 351: 453-456.
9. McNutt NS, Saenz-Santamaria C, Volkenandt M, et al. Abnormalities of P53 expression in cutaneous disorders. Arch Dermatol 1994; 130: 225-232.
10. Liang S, Ohtsuki Y, Furihata M, et al. Sun exposure and aging-dependent P53 protein accumulation results in growth advantage for tumour cells in carcinogenesis of nonmelanocytic skin cancer. Virchows Arch 1999; 434: 193-199.
11. Cagnoni ML, Ghersetich I, Lotti T, et al. Treatment of psoriasis vulgaris with topical calcipotriol: Is the clinical improvement of lesional skin related to a down-regulation of cell adhesion molecules? Acta Derm Venereol 1994; 186: 55-57.
12. Mozzanica N, Cattaneo A, Schmitt E, et al. Topical calcipotriol for psoriasis - an immunohistologic study. Acta Derm Venereol 1994; 186: 171-172.
13. 3 and calcipotriol-induced IL-10 receptor gene expression in human epidermal cells. Inflamm Res 1997; 46: 32-34.
14. Romer J, Hasselager E, Norby PL, et al. Epidermal over-expression of interleukin-19 and -20 mRNA in psoriatic skin disappears after short-term treatment with cyclosporine-A or calcipotriol. J Invest Dermatol 2003; 121: 1306-1311.
15. Fredriksson T, Pettersson U. Severe psoriasis- oral therapy with a new retinoid. Dermatologica 1978; 157: 238-244.
16. Kikuchi A, Nishikawa T. Apoptotic and proliferating cells in cutaneous lymphoproliferative diseases. Arch Dermatol 1997; 133: 829-833.
17. Fogh K, Kragballe K. New vitamin D analogs in psoriasis. Curr Drug Target Inflamm Allergy 2004; 3: 199-204.
18. Ragaz A, Ackerman AB. Evolution, maturation and regression of lesions of psoriasis. New observations and correlation of clinical and histologic findings. Am J Dermatopathol 1979; 1: 199-214.
19. Soini Y, Kamel D, Paakko P, et al. Aberrant accumulation of P53 associates with Ki67 and mitotic count in benign skin lesions. Br J Dermatol 1994; 131: 514-520.
20. El-Domyati M, Attia S, Saleh F, et al. Expression of P53 in normal sun-exposed and protected skin (type IV-V) in different decades of age. Acta Derm Venereol 2003; 83: 98-104.
21. El-Domyati MM, Attia SK, Saleh FY, et al. Effect of topical tretinoin, chemical peeling and dermabrasion on P53 expression in facial skin. Eur J Dermatol 2003; 13: 433-438.
22. Tadini G, Cerri A, Crosti L, et al. P53 and oncogenes expression in psoriasis. Acta Derm Venereol 1989; 146: 33-35.
23. Hannuksela-Svahn A, Paakko P, Autio P, et al. Expression of P53 protein before and after PUVA treatment in psoriasis. Acta Derm Venereol 1999; 79: 195-199.
24. Nakagawa K, Yamamura K, Maeda S, et al. Bcl-2 expression in epidermal keratinocytic disease. Cancer 1994; 74: 1720-1724.
25. Wrone-Smith T, Mitra RS, Thompson CB, et al. Keratinocytes derived from psoriatic plaques are resistant to apoptosis compared with normal skin. Am J Pathol 1997; 15: 1321-1329.
26. Lu QL, Poulsom R, Wong L, et al. Bcl-2 expression in adult and embryonic non-haematopoietic tissues. J Pathol 1993; 169: 431-437.
27. Tomkova H, Fujimoto W, Arata J. Expression of Bcl-2 antagonist bak in inflammatory and neoplastic skin diseases. Br J Dermatol 1997; 37: 703-708.
28. Audo I, Darjatmoko SR, Schlamp CL, et al. Vitamin D analogues increase P53, P21 and apoptosis in a xenograft model of human retinoblastoma. Invest Ophthalmol Vis Sci 2003; 44: 4192-4199.
29. Diaz GD, Paraskeva C, Thomas MG, et al. Apoptosis is induced by the active metabolite of vitamin D3 and its analogue EB1089 in colorectal adenoma and carcinoma cells: Possible implications for prevention and therapy. Cancer Res 2000; 60: 2304-2312.
30. Teraki Y, Shiohara T. Apoptosis and the skin. Eur J Dermatol 1999; 9: 413-425.